Tumour‐associated B cells in urothelial urinary bladder cancer

Zirakzadeh, Ali; Sherif, Amir; Rosenblatt, Robert; Bergman, Emma Ahlén; Winerdal, Max; Yang, David Y.; Cederwall, Johanna; Jakobsson, Vivianne; Hyllienmark, Martin; Winqvist, Ola; Marits, Per

doi:10.1111/sji.12830

Cited by 30 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, in this high IgG and C1q positive tumors, almost 40% also present membranous staining with an anti-C3a detecting antibody. This study suggests the possibility that the activation of the classical pathway could be favorable for the patient's survival [35]. However, recent studies revealed that in lung and renal cancers the activation of the classical pathway by intratumoral immunoglobulins is associated with poor prognosis [23,34].…”

Section: Activation Of Complement In the Tumor Microenvironmentmentioning

confidence: 74%

“…In non-small cell lung cancer (NSCLC), IgM deposits are observed, pointing to a potential binding of the IgM to the neoantigens present at the tumor cell surface and a triggering of the classical pathway activation [34]. Furthermore, in human urothelial urinary bladder cancer, 50% of tumors with high levels of IgG antibodies also display C1q [35]. Interestingly, in this high IgG and C1q positive tumors, almost 40% also present membranous staining with an anti-C3a detecting antibody.…”

Section: Activation Of Complement In the Tumor Microenvironmentmentioning

confidence: 99%

See 1 more Smart Citation

Complement System: Promoter or Suppressor of Cancer Progression?

et al. 2020

View full text Add to dashboard Cite

Constituent of innate immunity, complement is present in the tumor microenvironment. The functions of complement include clearance of pathogens and maintenance of homeostasis, and as such could contribute to an anti-tumoral role in the context of certain cancers. However, multiple lines of evidence show that in many cancers, complement has pro-tumoral actions. The large number of complement molecules (over 30), the diversity of their functions (related or not to the complement cascade), and the variety of cancer types make the complement-cancer topic a very complex matter that has just started to be unraveled. With this review we highlight the context-dependent role of complement in cancer. Recent studies revealed that depending of the cancer type, complement can be pro or anti-tumoral and, even for the same type of cancer, different models presented opposite effects. We aim to clarify the current knowledge of the role of complement in human cancers and the insights from mouse models. Using our classification of human cancers based on the prognostic impact of the overexpression of complement genes, we emphasize the strong potential for therapeutic targeting the complement system in selected subgroups of cancer patients.

show abstract

Section: Activation Of Complement In the Tumor Microenvironmentmentioning

confidence: 74%

Section: Activation Of Complement In the Tumor Microenvironmentmentioning

confidence: 99%

Complement System: Promoter or Suppressor of Cancer Progression?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…B cell is a prognostic factor in many cancers (such as high grade serous ovarian cancer) [ 44 ]. CD20 B cells have also been reported to be associated with longer survival in bladder cancer [ 45 ]. Bladder cancer has a certain response to immunotherapy, but there is a lack of unique immune prognostic biomarker to guide treatment [ 46 ].…”

Section: Discussionmentioning

confidence: 99%

A robust 11-genes prognostic model can predict overall survival in bladder cancer patients based on five cohorts

Lin

Yang

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background Bladder cancer is the tenth most common cancer globally, but existing biomarkers and prognostic models are limited. Method In this study, we used four bladder cancer cohorts from The Cancer Genome Atlas and Gene Expression Omnibus databases to perform univariate Cox regression analysis to identify common prognostic genes. We used the least absolute shrinkage and selection operator regression to construct a prognostic Cox model. Kaplan–Meier analysis, receiver operating characteristic curve, and univariate/multivariate Cox analysis were used to evaluate the prognostic model. Finally, a co-expression network, CIBERSORT, and ESTIMATE algorithm were used to explore the mechanism related to the model. Results A total of 11 genes were identified from the four cohorts to construct the prognostic model, including eight risk genes (SERPINE2, PRR11, DSEL, DNM1, COMP, ELOVL4, RTKN, and MAPK12) and three protective genes (FABP6, C16orf74, and TNK1). The 11-genes model could stratify the risk of patients in all five cohorts, and the prognosis was worse in the group with a high-risk score. The area under the curve values of the five cohorts in the first year are all greater than 0.65. Furthermore, this model’s predictive ability is stronger than that of age, gender, grade, and T stage. Through the weighted co-expression network analysis, the gene module related to the model was found, and the key genes in this module were mainly enriched in the tumor microenvironment. B cell memory showed low infiltration in high-risk patients. Furthermore, in the case of low B cell memory infiltration and high-risk score, the prognosis of the patients was the worst. Conclusion The proposed 11-genes model is a promising biomarker for estimating overall survival in bladder cancer. This model can be used to stratify the risk of bladder cancer patients, which is beneficial to the realization of individualized treatment.

show abstract

“…Fucoidans play significant roles in mutation of dendritic cells, activity of T and B lymphocytes, macrophages, and natural killer cells, and differentiation of macrophages in different experimental models, including cancer xenograft models [12,99,[108][109][110]. Importantly, such an immune system is closely associated with malignant potential and outcome of BC cells [111][112][113][114]. Additionally, immune therapy is currently recognized as a major treatment in patients with BC [115,116].…”

Section: Future Directionsmentioning

confidence: 99%

Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer

Miyata

Matsuo

Ohba

et al. 2020

Cancers

View full text Add to dashboard Cite

Bladder cancer (BC) is a common urological cancer, with poor prognosis for advanced/metastatic stages. Various intensive treatments, including radical cystectomy, chemotherapy, immune therapy, and radiotherapy are commonly used for these patients. However, these treatments often cause complications and adverse events. Therefore, researchers are exploring the efficacy of natural product-based treatment strategies in BC patients. Fucoidan, derived from marine brown algae, is recognized as a multi-functional and safe substrate, and has been reported to have anti-cancer effects in various types of malignancies. Additionally, in vivo and in vitro studies have reported the protective effects of fucoidan against cancer-related cachexia and chemotherapeutic agent-induced adverse events. In this review, we have introduced the anti-cancer effects of fucoidan extracts in BC and highlighted its molecular mechanisms. We have also shown the anti-cancer effects of fucoidan therapy with conventional chemotherapeutic agents and new treatment strategies using fucoidan-based nanoparticles in various malignancies. Moreover, apart from the improvement of anti-cancer effects by fucoidan, its protective effects against cancer-related disorders and cisplatin-induced toxicities have been introduced. However, the available information is insufficient to conclude the clinical usefulness of fucoidan-based treatments in BC patients. Therefore, we have indicated the aspects that need to be considered regarding fucoidan-based treatments and future directions for the treatment of BC.

show abstract

Tumour‐associated B cells in urothelial urinary bladder cancer

Cited by 30 publications

References 44 publications

Complement System: Promoter or Suppressor of Cancer Progression?

Complement System: Promoter or Suppressor of Cancer Progression?

A robust 11-genes prognostic model can predict overall survival in bladder cancer patients based on five cohorts

Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer

Contact Info

Product

Resources

About